These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 3817034)

  • 1. Bendazac prevents cyanate binding to soluble lens proteins and cyanate-induced phase-separation opacities in vitro: a possible mechanism by which bendazac could delay cataract.
    Lewis BS; Rixon KC; Harding JJ
    Exp Eye Res; 1986 Dec; 43(6):973-9. PubMed ID: 3817034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspirin prevents carbamylation of soluble lens proteins and prevents cyanate-induced phase separation opacities in vitro: a possible mechanism by which aspirin could prevent cataract.
    Crompton M; Rixon KC; Harding JJ
    Exp Eye Res; 1985 Feb; 40(2):297-311. PubMed ID: 3979467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The major metabolite of bendazac inhibits the glycosylation of soluble lens proteins: a possible mechanism for a delay in cataractogenesis.
    Lewis BS; Harding JJ
    Exp Eye Res; 1988 Aug; 47(2):217-25. PubMed ID: 3409993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibuprofen, a putative anti-cataract drug, protects the lens against cyanate and galactose.
    Roberts KA; Harding JJ
    Exp Eye Res; 1990 Feb; 50(2):157-64. PubMed ID: 2311679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reaction of aspirin with cysteinyl residues of lens gamma-crystallins: a mechanism for the proposed anti-cataract effect of aspirin.
    Qin W; Smith JB; Smith DL
    Biochim Biophys Acta; 1993 Apr; 1181(2):103-10. PubMed ID: 8481398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bendazac decreases in vitro glycation of human lens crystallins. Decrease of in vitro protein glycation by bendazac.
    Marques C; Ramalho JS; Pereira P; Mota MC
    Doc Ophthalmol; 1995; 90(4):395-404. PubMed ID: 8620822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of bendazac L-lysine salt on X-ray-induced cataract in the rabbit lens.
    Pandolfo L; Livrea MA; Bono A
    Exp Eye Res; 1986 Feb; 42(2):167-75. PubMed ID: 3699106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aspirin prevents the nonenzymatic glycosylation and carbamylation of the human eye lens crystallins in vitro.
    Rao GN; Cotlier E
    Biochem Biophys Res Commun; 1988 Mar; 151(3):991-6. PubMed ID: 3355566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of bendazac L-lysine salt on some metabolic enzymes of glutathione in the rabbit lens after X-irradiation.
    Bono A; Militello A; Bongiorno A; Livrea MA; Pandolfo L
    Ital J Biochem; 1987; 36(3):153-65. PubMed ID: 3610598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Basic data supporting the use of the l-lysine salt of bendazac in cataract.
    Silvestrini B; Catanese B; Barillari G; Iorio E; Valeri P
    Int J Tissue React; 1983; 5(2):217-25. PubMed ID: 6618787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of 6-phosphogluconate dehydrogenase by carbamylation and protection by alpha-crystallin, a chaperone-like protein.
    Ganea E; Harding JJ
    Biochem Biophys Res Commun; 1996 May; 222(2):626-31. PubMed ID: 8670255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of aminoguanidine on the glycation (non-enzymic glycosylation) of lens proteins.
    Lewis BS; Harding JJ
    Exp Eye Res; 1990 May; 50(5):463-7. PubMed ID: 2373149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Photosensitized haemolysis of human erythrocytes is reduced by bendazac.
    Ciancarelli-Tozzi MG; Silvestrini B; Finazzi-Agro A
    Drugs Exp Clin Res; 1989; 15(5):219-22. PubMed ID: 2791873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-molecular-weight crystallin aggregate formation resulting from non-enzymic carbamylation of lens crystallins: relevance to cataract formation.
    Beswick HT; Harding JJ
    Exp Eye Res; 1987 Oct; 45(4):569-78. PubMed ID: 3428385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bendazac lysine. A review of its pharmacological properties and therapeutic potential in the management of cataracts.
    Balfour JA; Clissold SP
    Drugs; 1990 Apr; 39(4):575-96. PubMed ID: 2190795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacokinetics of bendazac-lysine and 5-hydroxybendazac, its main metabolite, in patients with hepatic cirrhosis.
    Rovei V; Escourrou J; Campistron G; Ego D; Thiola A; Ribet A; Houin G
    Eur J Clin Pharmacol; 1988; 35(4):391-6. PubMed ID: 3197747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of bendazac-lysine and 5-hydroxybendazac in patients with renal insufficiency.
    Rovei V; Campistron G; Dueymes JM; Ego D; Conte JJ; Houin G
    Eur J Clin Pharmacol; 1987; 33(3):303-10. PubMed ID: 3691618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antioxidant characteristics of some potential anticataract agents. Studies of aspirin, paracetamol, and bendazac provide support for an oxidative component of cataract.
    Woollard AC; Wolff SP; Bascal ZA
    Free Radic Biol Med; 1990; 9(4):299-305. PubMed ID: 2283086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acetylation of lens crystallins: a possible mechanism by which aspirin could prevent cataract formation.
    Rao GN; Lardis MP; Cotlier E
    Biochem Biophys Res Commun; 1985 May; 128(3):1125-32. PubMed ID: 4004853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bendazac and benzydamine for treatment of cataract: individualized therapy by the "BLOA test".
    Testa M; Iuliano G; Marino E; Buongiovanni C; Paolercio F; Trapanese A; Mortow P
    J Ocul Pharmacol; 1986; 2(3):251-66. PubMed ID: 3503111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.